Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial

OBJECTIVE: This phase II, single-arm, prospective study aimed to evaluate the efficacy and safety of anlotinib in Chinese patients with recurrent or metastatic cervical cancer (CC). METHODS: Patients with histologically proven recurrent or metastatic advanced CC were enrolled at Fudan University Sha...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jun, Song, Chunyan, Zheng, Zhong, Xia, Lingfang, Chen, Yanqiong, Ke, Guihao, Wu, Xiaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593387/
https://www.ncbi.nlm.nih.gov/pubmed/34796105
http://dx.doi.org/10.3389/fonc.2021.720343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593387/
https://www.ncbi.nlm.nih.gov/pubmed/34796105
http://dx.doi.org/10.3389/fonc.2021.720343

Ejemplares similares